Research Article

Silencing of NLRP3 Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin

Weijia Li, 1 Xibo Zhao, 2 Rujian Zhang, 3 Jiabin Xie, 3 and Guangmei Zhang 2

1Department of Gynecology, Harbin Medical University, Harbin, 150081 Heilongjiang, China
2Department of Gynecology, The First Affiliated Hospital of Harbin Medical University, Harbin, 150081 Heilongjiang, China
3Department of Gynecology, Southern Medical University Affiliated Maternal and Child Health Hospital of Foshan, Foshan, 528000 Guangdong, China

Correspondence should be addressed to Guangmei Zhang; guangmeizhang@126.com

Received 27 October 2022; Revised 16 January 2023; Accepted 25 March 2023; Published 2 June 2023

Academic Editor: Jinghua Pan

Copyright © 2023 Weijia Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Ovarian cancer is a fatal gynecological malignancy. The resistance to chemotherapy in ovarian cancer treatment has been a thorny issue. This study is aimed at probing the molecular mechanism of cisplatin (DDP) resistance in ovarian cancer.

Methods. Bioinformatics analysis was conducted to examine the role of Nod-like receptor protein 3 (NLRP3) in ovarian cancer. The NLRP3 level in DDP-resistant ovarian cancer tumors and cell lines (SKOV3/DDP and A2780/DDP) was evaluated by applying immunohistochemical staining, western blot, and qRT-PCR. Cell transfection was conducted to regulate the NLRP3 level. Cell abilities to proliferate, migrate, invade, and apoptosis were measured employing colony formation, CCK-8, wound healing, transwell, and TUNEL assays, respectively. Cell cycle analysis was completed via flow cytometry. Corresponding protein expression was measured by western blot. Results. NLRP3 was overexpressed in ovarian cancer, correlated with poor survival, and upregulated in DDP-resistant ovarian cancer tumors and cells. NLRP3 silencing exerted antiproliferative, antimirugative, anti-invasive, and proapoptotic effects in A2780/DDP and SKOV3/DDP cells. Additionally, NLRP3 silencing inactivated NLRP3 inflammasome and blocked epithelial-mesenchymal transition via enhancing E-cadherin and lowering vimentin, N-cadherin, and fibronectin. Conclusion. NLRP3 was overexpressed in DDP-resistant ovarian cancer. NLRP3 knockdown hindered the malignant process of DDP-resistant ovarian cancer cells, providing a potential target for DPP-based ovarian cancer chemotherapy.

1. Introduction

Ovarian cancer, well-prevalent gynecological oncology, is one of the main contributors to deaths associated with cancer in females worldwide [1, 2]. It is estimated that the new ovarian cancer cases may rise to 371000, and the number of deaths will be 254000 by 2035 [3]. Early ovarian cancer is not easily diagnosed due to ineffective screening means, [4] resulting in its development to an advanced stage when diagnosed. Surgical resection combined with cisplatin- (DDP-) based chemotherapy is the mainstay of ovarian cancer treatment. Nevertheless, 70%-90% of the patients relapse, and most develop resistance to the DPP challenge, which takes the main responsibility for the treatment failure and the poor 5-year survival rate below 40% [5, 6]. Thus, clarifying the potential mechanism of chemoresistance and developing effective strategies for reducing DDP resistance in ovarian cancer are quite essential.

Nod-like receptor protein 3 (NLRP3) inflammasome is a complex consisting of NLRP3, the adaptor apoptosis-associated speck-like protein (ASC), and the effector pro-caspase. NLRP3 inflammasome activation facilitates the formation of active caspase-1 and contributes to the maturity and production of interleukin (IL)-18 and IL-1β, eventually leading to inflammation [7–9]. As a crucial constituent of the innate immune system, the NLRP3 inflammasome frequently
responds to cellular damage and microbial infection [10]. Recently, emerging evidence revealed that NLRP3 inflamma-
osome was dysregulated during tumor development. For example, NLRP3 was overexpressed in colon cancer cells
and linked to the poor survival of patients [11, 12]. NLRP3 inflamma-
some was activated in gastric cancer, which was benefi-

cial in promoting tumorigenesis [13]. On the contrary, NLRP3 inflamma-
some was downregulated in human hep-

tocellular carcinoma, and the absent NLRP3 was linked to
advanced stages [14]. Thus, attributed to the dual role in
different types of malignant tumor, NLRP3 inflamma-
some was regarded as a double-edged sword in tumorigen-

esis. The graphical

ow chart has been illustrated in

Scheme 1.

2. Methods and Materials

2.1. Bioinformatics Analysis. Gene Expression Omnibus
(GEO; https://www.ncbi.nlm.nih.gov/geo/) database includes
experimental data for genomic DNA and proteins and data
from single- and dual-channel determination of mRNA
expression. Five expression profiling datasets (GSE26712,
GSE53963, GSE51088, GSE66957, and GSE135886) were
obtained from the GEO database. The expression data of
NLRP3 in ovarian cancer were analyzed using GEO2R online.
The figure construction was carried out, adopting R package
software 4.0.3. A total of 381 ovarian cancer cases and 71 nor-
mal cases were downloaded from The Cancer Genome Atlas
(TCGA) database (http://www.cancer.gov/tcga). The expres-
sion of NLRP3 in ovarian cancer tumor tissues and normal tis-

ues was analyzed according to the downloaded data. The
clinical profile of 381 ovarian cancer patients was obtained
from the TCGA database, and the survival analysis was con-
ducted using the Kaplan-Meier method. The patients with
missing clinical data about tumor stages were excluded from
this study. A total of 377 samples (23 at stage II, 296 at stage
III, and 58 at stage IV) were examined for NLRP3 level at
different tumor stages. Moreover, a single-variable Cox pro-
portional risk regression assay was conducted to explore the
risk factors that were remarkably correlated with overall sur-
vival in TCGA ovarian cancer dataset. In addition, Tumor
Immunization Estimation Resource (TIMER; http://timer.
cistrome.org), a comprehensive database to assess the rela-
tionship between immune infiltrating cells and overall sur-
vival of cancers, was applied to estimate the infiltration of
CD8+ T cells, CD4+ T cells, B cells, neutrophils, macrophage,
and myeloid dendritic cells related to NLRP3 level in ovarian
cancer patients.

2.2. Tissue Samples. A total of 36 ovarian cancer specimens
were collected from patients receiving oophorectomies from
2021.1 to 2022.10 at Foshan Women and Children Hospital.
Among these specimens, 18 were harvested from DDP-
resistant patients suffering from recurrent or persistent dis-
ease within 6 months following DDP-based chemotherapy.
The other was collected from DDP-sensitive (nonresistant) patients without recurrence or with recurrence beyond 6
months. The patient’s clinical information is listed in
Table 1. The study was approved by the Ethics Committees
of Foshan Women and Children Hospital (Approval number:
FSFY-MEC-2021-145), and written consent was acquired
from all patients.

2.3. Immunohistochemical Staining. The tissue was fixed in
4% paraformaldehyde for 24 h, embedded in paraffin, and
sliced to a thickness of 5 μm. Subsequently, the slices were
deparaffinized and rehydrated, followed by heating in
0.01 M citric buffer for 15 min. Before probing overnight at
4°C with anti-NLRP3 antibody (ab263899, Abcam), the
slices were impeded in 3% H2O2 for 20 min and then with
5% normal serum for 30 min. Thereafter, the slices were
probed with horseradish peroxidase- (HRP-) conjugated
secondary antibody (ab6721, Abcam) for 30 min, diamino-
benzidine (DAB) stained (ZSGB-BIO, Beijing, China) for
5 min followed by hematoxylin counterstaining for 30 s.
Eventually, the images were obtained utilizing a light micro-
scope (Olympus, Tokyo, Japan).

2.4. Quantitative Real-Time Polymerase Chain Reaction
(qRT-PCR). RNA content was exacted from the tumor tis-

es adopting Trizol (Thermo Fisher Scientific, CA, USA).
The concentration and purity of the total RNA were checked
using NanoDrop 3000 (Thermo Fisher Scientific Inc., Wal-
tham, MA, USA). The RNA content was reversely tran-
scribed into complementary DNA (cDNA) adopting a
cDNA synthesis kit (Thermo Fisher Scientific Inc.), followed
by qRT-PCR analysis utilizing SYBR Green Master Mix
(Takara, Shiga, Japan). The primers of PCR are listed in
Table 2. 2–1/△△Ct method was utilized for calculating gene
expressions using β-actin as an internal reference.

2.5. Western Blot. RIPA lysis buffer (Bolingkewei, Beijing,
China) was applied to homogenize the tissues. The whole pro-
tein was extracted and quantified using a bicinchoninic acid
(BCA) protein assay kit (Pierce, Rockford, IL, USA). The pro-
tein (35 μg/lane) was isolated through 12% SDS-PAGE gels,
followed by transferring onto polyvinylidene difluoride
(PVDF) membranes (Millipore, MA, USA). After 1 h incuba-
tion with 5% defatted milk, membranes were probed at 4°C
overnight against the following antibodies: NLRP3 (ab263899,
Abcam), IL-1β (ab2413, Abcam), N-cadherin (ab76011, Abcam), E-cadherin (ab40772, Abcam), fibronectin
(ab2413, Abcam), vimentin (ab92547, Abcam), and β-actin
(ab8226, Abcam). On the following day, membranes were
exposed to goat anti-mouse (ab6789, Abcam) or goat anti-
rabbit (ab6721, Abcam) HRP-conjugated secondary antibodies
for 2 h at room temperature. Eventually, the signals were
2.8. Cell Counting Kit-8 (CCK-8) Assay. 5 × 10³ cells were plated in 6-well plates and then cultivated for ten days. The absorbance was tested at 450 nm with the help of a microplate reader (Bio-Rad Laboratories, Hercules, CA).

2.9. Colony Formation Assay. 2 × 10³ cells were plated in 6-well plates and then cultivated for ten days. The absorbance was tested at 450 nm with the help of a microplate reader (Bio-Rad Laboratories, Hercules, CA).

2.10. Wound-Healing Assay. 5 × 10⁴ cells were cultivated into 6-well plates in a 5% CO₂ incubator at 37°C. Upon achieving 100% confluence, a sterile pipette tip was adopted to create linear scratches. PBS washed the plates carefully to discard the floating cells. 24 h later, the healing of the scratches was observed and photographed employing a light microscope (Olympus, Tokyo, Japan).

2.11. Transwell Assay. A 24-well insert transwell chamber (Millipore, MA, USA) was coated with 200 mg/ml Matrigel (BD Biosciences, NY, USA). 5 × 10⁴ cells were resuspended in serum-free medium and placed into the upper transwell chamber, while 500 μL medium with 10% FBS was put into the lower chamber. 24 h later, after wiping out the noninvasive cells, the cells got a fixation with 4% paraformaldehyde, followed by 0.5% crystal violet staining. Images of invaded cells were photographed by a light microscope (Olympus, Tokyo, Japan).

2.12. Terminal Deoxynucleotidyl Transferase-Mediated dUTP Nick End Labeling (TUNEL) Staining. 4% paraformaldehyde was utilized to fix cells. 20 min later, cells underwent permeabilization using 0.1% Triton X-100 for 30 minutes and inactivated endogenous peroxidase by 0.3% H₂O₂ for 20 minutes. Afterward, the TUNEL mixture solution (Beyotime and Biotechnology, Shanghai, China) was added, and the cells were incubated for 1 h at 37°C in the darkness. 4′, 6-diamidino-2-phenylindole (DAPI) solution was added to stain cells. The images were captured adopting an Olympus IX70 inverted microscope (Olympus, Tokyo, Japan).

2.13. Flow Cytometry Analysis. Cells were washed with pre-cooled PBS at 4°C, followed by fixation in 70% ethanol overnight at 4°C. After that, cells were stained with 50 μg/mL propidium iodide (PI) containing RNase (Beyotime and Biotechnology, Shanghai, China) for 30 min in the darkness. The cell cycle was measured adopting flow cytometry (FACSCalibur, Becton-Dickinson) and analyzed using FlowJo software (Leonard Herzenberg, Stanford University, USA).

2.14. Statistical Analysis. All data analyzed by GraphPad Prism 8.0 (GraphPad, CA, USA) were presented as mean ± standard deviation. Group comparisons were evaluated by adopting a one-way analysis of variance (ANOVA) with Tukey’s post hoc test. p < 0.05 meant statistically significant.

3. Results

3.1. NLRP3 Is Overexpressed in Ovarian Cancer and Linked to Poor Prognosis. Based on the indicated role of NLRP3 in
malignant diseases, we analyzed the expression profile of NLRP3 in ovarian cancer depending on GEO and TCGA databases. As shown in Figure 1(a), the public data from the GEO data portal revealed that NLRP3 expression was upregulated in tumor tissues of ovarian cancer, compared to the normal, which was concordant with the findings from the TCGA database (Figure 1(b)). Meanwhile, the expression level of NLRP3 was increasing from stage II to stage IV of ovarian cancer patients (Figure 1(c)), suggesting that NLRP3 was positively linked to the deterioration of ovarian cancer. The survival assay followed by Cox regression analysis revealed that patients with a higher level of NLRP3 had a poorer survival probability, and NLRP3 might act as an independent prognostic gene in ovarian cancer (Figures 1(d) and 1(e)). Finally, immune infiltration analysis using TIMER2 found that NLRP3 expression levels were significantly positively linked to the proportions of T cells, neutrophils, macrophages, and myeloid dendritic cells in ovarian cancer tissues (Figure 1(f)).

3.2. NLRP3 Is Upregulated in DDP-Resistant Ovarian Cancer. To understand the role of NLRP3 in DDP-resistant ovarian cancer, we first detected NLRP3 levels in patients with DPP resistance. As shown in Figure 2(a), the NLRP3 level in DDP-resistant tumor tissues was greatly higher than that in nonresistant tissues. Subsequently, three unpaired tumor tissues from DDP-resistant and non-resistant patients were randomly measured, employing immunohistochemical staining and western blot. It was observable that the NLRP3 level was remarkably upregulated in resistant tissues (Figures 2(b) and 2(c)). Furthermore, we evaluated the NLRP3 level in ovarian cancer cell lines (A2780 and SKOV3) and their DDP-resistant forms and found that NLRP3 was upregulated in A2780/DDP and SKOV3/DDP cells (Figures 2(d) and 2(e)).

3.3. Silencing of NLRP3 Retard Cell Proliferation and Cell Cycle Progression in DDP-Resistant Ovarian Cancer Cells. Next, a series of cellular biological activities were measured to assess the regulation of NLRP3 in DDP-resistant ovarian cancer. A2780/DDP and SKOV3/DDP cells were transfected with sh-NLRP3 to knock down NLRP3. Attributed to a relatively high transfection efficacy, sh-NLRP3-1 was selected in the following experiments (Figure 3(a)). The findings, as shown in Figure 3(b), revealed that the cell viability in the sh-NLRP3 group was significantly reduced in A2780/DDP and SKOV3/DDP cells compared to the sh-vector group. Meanwhile, the colonies were also lessened following NLRP3 knockdown (Figures 3(c) and 3(d)). In addition, flow cytometry analysis exhibited an elevated cell cycle arrest in G0/G1 phase, accompanied by a reduced cell proportion in the S phase after NLRP3 knockdown in both A2780/DDP and SKOV3/DDP cells (Figures 3(e) and 3(f)), suggesting that the cell cycle progression was blocked by NLRP3 knockdown in DPP-resistant ovarian cancer cells.

3.4. Silencing of NLRP3 Represses Cell Invasion and Migration While Promoting Apoptosis in DDP-Resistant Ovarian Cancer Cells. Subsequently, a series of cellular behaviors were examined to assess cell migration, invasiveness, and apoptosis changes after NLRP3 silencing. As presented in Figures 4(a) and 4(b), the healing of the scratch was hindered in the sh-NLRP3 group compared to the sh-vector group in both SKOV3/DDP and A2780/DDP cells, suggesting that the migration ability of these DDP-resistant cells was weakened following NLRP3 knockdown. Meanwhile, the less invasive cells observed in the sh-NLRP3 group in Figure 4(c) indicate that NLRP3 silencing weakened the invasive ability of DDP-resistant ovarian cancer cells. Afterward, Figure 4(e) revealed that the silencing of NLRP3 caused a remarkable elevation of TUNEL-positive cells in SKOVE/DDP cells but not A2780/DDP cells.

3.5. Silencing of NLRP3 Inactivates NLRP3 Inflammasome in DDP-Resistant Ovarian Cancer Cells. As NLRP3 is a crucial component of the NLRP3 inflammasome, we examined the impact of NLRP3 silencing on the NLRP3 inflammasome. Figure 5 shows that the expression level of NLRP3, IL-1β, and cleaved caspase-1 was significantly reduced following NLRP3 knockdown in both SKOVE/DDP and A2780/DDP cells, demonstrating that silencing of NLRP3 inactivated NLRP3 inflammasome in DDP-resistant ovarian cancer cells.

3.6. Silencing of NLRP3 Suppresses Epithelial-Mesenchymal Transition (EMT) in DDP-Resistant Ovarian Cancer Cells. EMT is an early event of tumor invasion and metastasis [19]; hence, we examined the impacts of NLRP3 silencing on EMT markers. As exhibited in Figure 6, the epithelial marker E-cadherin was significantly upregulated following NLRP3 silencing, but the expression level of N-cadherin, fibronectin, and vimentin, the mesenchymal markers, were markedly lowered following NLRP3 knockdown, indicating that NLRP3 knockdown reversed EMT in DDP-resistant ovarian cancer cells.

4. Discussion
Ovarian cancer is a fatally gynaecological malignant tumor. Attributed to drug resistance, it is hard to completely cure, leading to recurrences, metastasis, and poor survival rate of ovarian cancer [20]. Hence, it is essential to elucidate the drug-resistance mechanism and to prevent drug resistance in ovarian cancer. Here, it is the first time to be verified that NLRP3 serves a vital role in DDP-based chemoresistance of ovarian cancer. The findings revealed that NLRP3 was overexpressed in response to DDP-resistant ovarian cancer. NLRP3 knockdown could effectively block cell proliferation, invasion, and EMT, while it promotes apoptosis in ovarian cancer cells with DDP resistance. Collectively, the data revealed that NLRP3 knockdown and the inactivation of NLRP3 inflammasome might weaken the malignant phenotype of ovarian cancer with DDP resistance and regulate the chemoresistance of ovarian cancer cells to DDP-based therapy.

The involvement of NLRP3 inflammasome in tumor initiation and development of different types of cancer has been widely addressed, especially its dual role in cancers as aforementioned. As drug resistance strictly limits the therapeutic
Figure 1: NLRP3 is overexpressed in ovarian cancer and linked to poor prognosis. (a) The gene expression data for ovarian cancer patients with NLRP3 expression information (GSE26712, GSE53963, GSE51088, GSE66957, and GSE135886) were obtained from the NCBI GEO database. (b) The expression profile of NLRP3 in ovarian cancer from TCGA database. (c) NLRP3 level in different clinical stages of patients with ovarian cancer. (d) The survival rate analysis of NLRP3 level and ovarian cancer patients. (e) Cox regression analysis of NLRP3 in ovarian cancer. (f) TIMER database was adopted to assess the association between NLRP3 level and immune infiltrates' abundances in ovarian cancer.
The efficacy of chemotherapy and seriously harms patients’ health and life, increasing attention has been paid to whether NLRP3 can also regulate the malignant processes against drug resistance in cancer. For instance, the activated NLRP3 inflammasome facilitated leukemia cell proliferation and improved chemotherapy resistance, while the inactivation of NLRP3 exerted the opposite effects, demonstrating the promotive effects of NLRP3 on cancer development and chemotherapy resistance in acute myeloid leukemia [21]. Meanwhile, NLRP3 was reported to enhance gemcitabine-based resistance in triple-negative breast cancer cells [22]. In addition, it was proved that NLRP3 inflammasome could promote resistance of 5-fluorouracil to oral squamous cell carcinoma [23]. The existing evidence suggested that NLRP3 inflammasome might be an effective target for the adjuvant chemotherapy of multiple types of cancer. Regarding ovarian cancer, it was only reported by Alrashed et al. that NLRP3 could improve the gemcitabine sensitivity in gemcitabine-resistant ovarian cancer cell lines [20], but whether NLRP3 inflammasome also exerted critical effects on DDP resistance in ovarian cancer remained unclear. Here, a high level of NLRP3 was found in DPP-resistant ovarian tumors, whereas NLRP3 silencing can suppress cell proliferation, invasion, and migration and promote apoptosis of SKOV3/DDP and A2780/DDP cells. The abovementioned findings suggest that downregulation of NLRP3 repressed the malignant processes of DPP-resistant ovarian cancer cells, which might be beneficial to improve the

**Figure 2:** NLRP3 is upregulated in DPP-resistant ovarian cancer. (a) The tumor tissues from ovarian cancer patients with DDP resistance or not were collected, and the mRNA level of NLRP3 in tumor tissues was assessed by qRT-PCR. (b) The NLRP3 expression in tumor tissues was assessed using a western blot. (c) The NLRP3 expression in tumor tissues was observed using immunohistochemical staining. (d) The NLRP3 level in A2780 and SKOV3 and the DDP-resistant ovarian cancer cells was assessed, adopting qRT-PCR. (e) The NLRP3 expression in A2780 and SKOV3 and the DDP-resistant ovarian cancer cells was assessed adopting a western blot. **p < 0.01, and ***p < 0.001.
antitumor effects of DDP against DDP-resistant patients with ovarian cancer.

EMT, an early event of tumor invasion and metastasis [19], is a fundamental developmental process wherein epithelial cells lose their polarity and gain invasiveness, eventually leading to the transformation into mesenchymal cells, which has been recognized as a major approach to propagating tumor dissemination. Therefore, along with this condition, the classical epithelial marker E-cadherin was downregulated, while mesenchymal markers, including fibronectin, vimentin, and N-cadherin, were upregulated [24–26]. Currently, EMT is considered a crucial indicator for not only cancer development but also drug resistance. Resistance to DDP-based chemotherapy in ovarian cancer

![Graphs and images](https://example.com/fig3.png)

**Figure 3:** Silencing of NLRP3 suppressed cell proliferation and cell cycle progression in DDP-resistant ovarian cancer cells. (a) Both A2780/DDP and SKOV3/DDP cells received transfection using sh-NLRP3-1 and sh-NLRP3 to knock down NLRP3, and the mRNA level of NLRP3 was detected using qRT-PCR. (b) The cell viability was assessed, adopting CCK-8 assay. (c, d) Colony formation assay was conducted to examine cell proliferation. (e, f) Cell cycle was assessed using flow cytometry. *p < 0.05, **p < 0.01, and ***p < 0.001.
Figure 4: Silencing of NLRP3 repressed cell invasion and migration while facilitated apoptosis in DDP-resistant ovarian cancer cells. (a, b) Cell ability to migrate was assessed, adopting a wound-healing assay. (c, d) Cell ability to invade was assessed, adopting transwell assay. (e) TUNEL assay was carried out to detect cell apoptosis and apoptosis. *p < 0.05, **p < 0.01, and ***p < 0.001.
was linked to EMT [27]. Blocking PI3K/Akt/mTOR signaling pathway attenuates ovarian cancer chemoresistance to DDP through reversing EMT [28]. Consistently, we also observed a restoration of EMT following NLRP3 silencing in DDP-resistant ovarian cancer cells in this study, as proved by the elevated level of E-cadherin and the reduced level of N-cadherin, vimentin, and fibronectin, suggesting that NLRP3 knockdown might alleviate resistance towards ovarian cancer via reversing EMT.

However, some limitations still exist in the present study. First, in vivo assay may be beneficial to validate the current findings in vitro. Secondly, this study preliminarily explored the molecular mechanism of NLRP3 in DDP-resistant ovarian cancer, and the in-depth research focusing on its potential mechanism is deserved to be conducted in our future work.

5. Conclusion

Taken together, the current research highlights the specific role of NLRP3 in DDP-resistant ovarian cancer. Silencing of NLRP3 can weaken drug resistance through repressing cell proliferation, invasion, and EMT in DDP-resistant ovarian cancer cells. NLRP3 is suggested to be a target for monitoring DDP resistance in ovarian cancer and improving therapeutic outcomes.

Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>DDP</td>
<td>Cisplatin</td>
</tr>
<tr>
<td>NLRP3</td>
<td>Nod-like receptor protein 3</td>
</tr>
<tr>
<td>qRT-PCR</td>
<td>Quantitative real-time PCR</td>
</tr>
<tr>
<td>EMT</td>
<td>Epithelial-mesenchymal transition</td>
</tr>
<tr>
<td>IL-18</td>
<td>Interleukin-18</td>
</tr>
<tr>
<td>DAB</td>
<td>Diaminobenzidine</td>
</tr>
<tr>
<td>PVDF</td>
<td>Polyvinylidene difluoride</td>
</tr>
<tr>
<td>TBST</td>
<td>Tris-buffered saline and Tween-20</td>
</tr>
<tr>
<td>sh-NLRP3</td>
<td>Short hairpin RNA targeting NLRP3</td>
</tr>
<tr>
<td>sh-vector</td>
<td>Empty vector</td>
</tr>
<tr>
<td>CCK-8</td>
<td>Cell counting kit-8</td>
</tr>
<tr>
<td>OD</td>
<td>Optical density</td>
</tr>
<tr>
<td>TUNEL</td>
<td>Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling</td>
</tr>
<tr>
<td>DAPI</td>
<td>4′,6-Diamidino-2-phenylindole</td>
</tr>
<tr>
<td>SD</td>
<td>Standard deviation</td>
</tr>
<tr>
<td>ANOVA</td>
<td>One-way analysis of variance</td>
</tr>
</tbody>
</table>
Data Availability

All data can be obtained from the corresponding author on reasonable request.

Conflicts of Interest

The authors declare that there is no potential interest.

Acknowledgments

This study was funded by the National Natural Science Foundation of China (81772780).

Supplementary Materials

Scheme 1. Inhibition of NLRP3 enhances the susceptibility of cisplatin-resistant ovarian cancer cells to cisplatin treatment. NLRP3 was overexpressed in DDP-resistant ovarian cancer and activated the assembly of NLRP3 inflammasome. NLRP3 inflammasome could promote cell proliferation, invasion, and metastasis of DDP-resistant ovarian cancer and inhibit apoptosis of DDP-resistant ovarian cancer. (Supplementary Materials)

References


